Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Once-weekly oral islatravir-lenacapavir maintains HIV-1 suppression as effectively as daily B/F/TAF in a phase 3 trial with 607 adults.
- Why it matters: Adherence challenges with daily regimens can limit HIV treatment success, highlighting the need for less frequent dosing options to improve long-term management.
- What they did: A 96-week, double-blind, randomized trial compared weekly ISL/LEN to daily B/F/TAF in adults with suppressed HIV-1, assessing viral suppression and safety outcomes.
- The result: The weekly regimen was noninferior, with no participants experiencing viral rebound at week 48, and similar safety profiles, supporting its potential as a convenient alternative.